Education
About Us
Working with TipRanks
Follow Us
Oncotelic Therapeutics Inc (OTLC)
:OTLC
OTLC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.07
Previous CloseN/A
Volume643.67K
Average Volume (3M)114.20K
Market Cap
$20.71M
Enterprise Value$41.17M
Total Cash (Recent Filing)$79.17K
Total Debt (Recent Filing)$16.75M
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
Aug 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding408,292,450
10 Day Avg. Volume199,337
30 Day Avg. Volume114,203
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)3.05
Price to Sales (P/S)0.00
P/FCF Ratio-37.95
Enterprise Value/Market Cap1.99
Enterprise Value/Revenue588.15
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Oncotelic Therapeutics News
PremiumCompany Announcements
Oncotelic Therapeutics Delays Yearly Report Filing
PremiumCompany Announcements
Oncotelic Therapeutics Secures Funds Through Equity SalesOptions Prices
Currently, No data available
---
Ownership Overview
OTLC FAQ
What was Oncotelic Therapeutics Inc’s price range in the past 12 months?
Oncotelic Therapeutics Inc lowest stock price was $0.02 and its highest was $0.07 in the past 12 months.
What is Oncotelic Therapeutics Inc’s market cap?
Oncotelic Therapeutics Inc’s market cap is $20.71M.
When is Oncotelic Therapeutics Inc’s upcoming earnings report date?
Oncotelic Therapeutics Inc’s upcoming earnings report date is Aug 25, 2025 which is in 34 days.
How were Oncotelic Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Oncotelic Therapeutics Inc overvalued?
According to Wall Street analysts Oncotelic Therapeutics Inc’s price is currently Overvalued.
Does Oncotelic Therapeutics Inc pay dividends?
Oncotelic Therapeutics Inc does not currently pay dividends.
What is Oncotelic Therapeutics Inc’s EPS estimate?
Oncotelic Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncotelic Therapeutics Inc have?
Oncotelic Therapeutics Inc has 408,292,450 shares outstanding.
What happened to Oncotelic Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oncotelic Therapeutics Inc?
Currently, no hedge funds are holding shares in OTLC
Company Description
Oncotelic Therapeutics Inc
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Technical Analysis
Tempest Therapeutics
―
Pulmatrix
―
Annovis Bio
―
Elevation Oncology
―
Cognition Therapeutics
―